Abstract | BACKGROUND: METHODS: Fifty female adult Wistar albino rats weighing between 220 and 260 g were included in the study and were divided into 5 groups as follows: Group S ( sham), Group C (control), Group T100 (100 mg/kg thymoquinone), Group T200 (200 mg/kg thymoquinone), and Group T400 (400 mg/kg thymoquinone). To begin the experiment, SCI was applied to all groups (with the exception of the sham group) following a mechanical and heat-cold test. Two weeks later, the mechanical and heat-cold tests were repeated, and a single normal saline dose was given to the sham and control groups, whereas 3 varying doses of thymoquinone were given to the other groups. The mechanical and heat-cold tests were repeated at 30, 60, 120, and 180 minutes after receiving thymoquinone. Finally, the animals were put to death via the removal of intracardiac blood. The levels of nitric oxide, total oxidant status, total antioxidant status, paraoxonase, malondialdehyde, tumor necrosis factor-α, and interleukin-1β were determined in all of the blood samples. RESULTS: CONCLUSIONS:
Thymoquinone is beneficial for decreasing experimental neuropathic pain following SCI. However, increasing the dose does not change the effect.
|
Authors | Feyzi Celik, Cüneyt Göçmez, Haktan Karaman, Kağan Kamaşak, Ibrahim Kaplan, Eşref Akıl, Adnan Tufek, Abdulmenap Guzel, Ertuğrul Uzar |
Journal | Current therapeutic research, clinical and experimental
(Curr Ther Res Clin Exp)
Vol. 76
Pg. 11-6
(Dec 2014)
ISSN: 0011-393X [Print] United States |
PMID | 25031663
(Publication Type: Journal Article)
|